Nuwiq for i.v. injection Drug use-result survey

Nuwiq for i.v. injection Drug use-result survey - Nuwiq for i.v. injection Drug use-result survey

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047344

Enrollment

Registered

2022-03-31

Start date

2022-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemophilia A

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: This drug administered patients with blood coagulation factor VIII (Haemophilia A) deficiency.

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Safety (Incidence of adverse reactions,Inhibitor development,Incidence of shock, anaphylactic reactions,Factors that may influence on safety)	—

Secondary

Measure	Time frame
Efficacy (Bleeding rate,Hemostasis evaluation)	—

Countries

Japan

Contacts

Public ContactTakuya Kitada

Fujimoto Pharmaceutical Corp. Department of Pharmacovigilance

pms@fujimoto-pharm.co.jp072-332-5151

Outcome results